MX2016005954A - Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa. - Google Patents

Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa.

Info

Publication number
MX2016005954A
MX2016005954A MX2016005954A MX2016005954A MX2016005954A MX 2016005954 A MX2016005954 A MX 2016005954A MX 2016005954 A MX2016005954 A MX 2016005954A MX 2016005954 A MX2016005954 A MX 2016005954A MX 2016005954 A MX2016005954 A MX 2016005954A
Authority
MX
Mexico
Prior art keywords
indoleamine
synthesis
dioxygenase inhibitor
dioxygenase
inhibitor
Prior art date
Application number
MX2016005954A
Other languages
English (en)
Other versions
MX366874B (es
Inventor
Weng Lingkai
Zhou Jiacheng
Tao Ming
Pan Yongchun
Frietze William
J Meloni David
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of MX2016005954A publication Critical patent/MX2016005954A/es
Publication of MX366874B publication Critical patent/MX366874B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a procesos e intermedios para elaborar 4-({2-[(aminosulfonil)amino]etil}amino)-N-(3-bromo-4-fluo rofenil)-N'-hidroxi-1,2,5-oxasiazol-3-carboximidamida, que es un inhibidor de indolamina 2,3-dioxigenasa útil en el tratamiento del cáncer y otros trastornos.
MX2016005954A 2013-11-08 2014-11-07 Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa. MX366874B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361901689P 2013-11-08 2013-11-08
PCT/US2014/064531 WO2015070007A1 (en) 2013-11-08 2014-11-07 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Publications (2)

Publication Number Publication Date
MX2016005954A true MX2016005954A (es) 2016-12-07
MX366874B MX366874B (es) 2019-07-29

Family

ID=52023608

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005954A MX366874B (es) 2013-11-08 2014-11-07 Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa.
MX2019008378A MX2019008378A (es) 2013-11-08 2016-05-06 Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008378A MX2019008378A (es) 2013-11-08 2016-05-06 Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa.

Country Status (31)

Country Link
US (3) US9321755B2 (es)
EP (2) EP3066085B1 (es)
JP (4) JP6461953B2 (es)
KR (2) KR102370067B1 (es)
CN (2) CN105899498B (es)
AR (1) AR098343A1 (es)
AU (2) AU2014346647B2 (es)
BR (2) BR122020009912B1 (es)
CA (1) CA2929552C (es)
CL (1) CL2016001082A1 (es)
CR (2) CR20160252A (es)
CY (1) CY1123164T1 (es)
DK (1) DK3066085T3 (es)
EA (2) EA201991770A1 (es)
ES (1) ES2799582T3 (es)
HR (1) HRP20201089T1 (es)
HU (1) HUE049337T2 (es)
IL (2) IL245314B (es)
LT (1) LT3066085T (es)
ME (1) ME03792B (es)
MX (2) MX366874B (es)
MY (1) MY174254A (es)
PE (2) PE20220430A1 (es)
PH (2) PH12016500818A1 (es)
PL (1) PL3066085T3 (es)
PT (1) PT3066085T (es)
RS (1) RS60598B1 (es)
SG (2) SG11201603433UA (es)
SI (1) SI3066085T1 (es)
TW (4) TWI651311B (es)
WO (1) WO2015070007A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034953B2 (en) 2005-05-10 2011-10-11 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
RS53688B9 (sr) 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
CA2938566A1 (en) * 2014-02-04 2015-08-13 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CA2992238A1 (en) * 2015-07-14 2017-01-19 Kyowa Hakko Kirin Co., Ltd. A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
CA3004083A1 (en) 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
EP3389783A4 (en) 2015-12-15 2019-05-15 Merck Sharp & Dohme Corp. NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
US9624185B1 (en) * 2016-01-20 2017-04-18 Yong Xu Method for preparing IDO inhibitor epacadostat
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2018036414A1 (zh) 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 稠杂环类衍生物、其制备方法及其在医学上的应用
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
WO2018095432A1 (en) 2016-11-28 2018-05-31 Shanghai Fochon Pharmaceutical Co., Ltd. Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2, 3-dioxygenase
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
CN109206380A (zh) * 2017-07-03 2019-01-15 上海时莱生物技术有限公司 吲哚胺2，3-双加氧酶抑制剂化合物及其制备方法和用途
CN110066253B (zh) * 2018-01-24 2023-06-23 江苏柯菲平医药股份有限公司 1,2,5-噁二唑类衍生物，其制备方法及其在医药中的应用
CN108101899B (zh) * 2018-02-11 2021-01-26 中国药科大学 IDO1抑制剂Epacadostat中间体的制备方法
CN109180603A (zh) * 2018-10-10 2019-01-11 中国药科大学 Epacadostat关键中间体的制备方法
CN114502196A (zh) 2019-08-01 2022-05-13 因赛特公司 Ido抑制剂的给药方案
JP2023501496A (ja) * 2019-11-14 2023-01-18 ノバ サウスイースタン ユニバーシティー Ｆ１６イソインドール小分子を使用する固形腫瘍の治療のための方法及び組成物
CN112341403B (zh) * 2020-11-10 2022-06-28 南京工业大学 一种利用微流场反应技术制备3-氨基-4-偕胺肟基呋咱的方法
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4301358A2 (en) 2021-03-05 2024-01-10 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236855A (en) 1964-01-17 1966-02-22 Merck & Co Inc Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3354174A (en) 1964-02-19 1967-11-21 Sterling Drug Inc 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines
US3553228A (en) 1967-09-26 1971-01-05 Colgate Palmolive Co 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles
DE2040628A1 (de) 1970-08-17 1972-02-24 Fahlberg List Veb Neue herbizide Mittel
US3948928A (en) 1972-03-17 1976-04-06 Dainippon Pharmaceutical Co., Ltd. 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof
JPS5621033B2 (es) 1973-09-05 1981-05-16
IE43624B1 (en) 1975-09-11 1981-04-22 Philagro Sa New derivatives of amidoximes
FR2323683A1 (fr) 1975-09-11 1977-04-08 Philagro Sa Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent
US4323681A (en) 1980-09-29 1982-04-06 American Home Products Corporation 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides
JPS58208275A (ja) 1982-05-20 1983-12-03 Lion Corp ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤
DE3462259D1 (de) 1983-07-22 1987-03-05 Bayer Ag Substituted furazans
US4507485A (en) 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
JPS60193968A (ja) 1984-03-13 1985-10-02 Toyo Jozo Co Ltd シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法
JPS6259283A (ja) 1985-09-10 1987-03-14 Kaken Pharmaceut Co Ltd セフアロスポリン化合物
JP2696342B2 (ja) 1988-06-27 1998-01-14 日本曹達株式会社 アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤
DE68901424D1 (de) 1988-07-05 1992-06-11 Akzo Nv Verbindungen mit bronchodilatatorischer aktivitaet.
JPH04297449A (ja) 1991-03-27 1992-10-21 Hokko Chem Ind Co Ltd Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤
JPH05186458A (ja) 1991-04-26 1993-07-27 Japan Tobacco Inc 新規なベンゾピラン誘導体
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
JP2709677B2 (ja) 1992-06-19 1998-02-04 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
FR2720396B1 (fr) 1994-05-27 1996-06-28 Adir Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5731315A (en) 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
JPH11513679A (ja) 1995-10-17 1999-11-24 アストラ・フアーマシユウテイカルズ・リミテツド 薬剤活性キナゾリン化合物
AU1730497A (en) 1996-02-17 1997-09-02 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
US5955495A (en) 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
JPH11171702A (ja) 1997-09-24 1999-06-29 Takeda Chem Ind Ltd 害虫防除方法
AU1628699A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
ES2213929T3 (es) 1997-12-10 2004-09-01 Dainippon Ink And Chemicals, Inc. Derivados de oximas y productos quimicos para uso agricola que incluyen los mismos.
KR20010052491A (ko) 1998-06-02 2001-06-25 다케다 야쿠힌 고교 가부시키가이샤 옥사디아졸린 유도체 및 살충제로서 이의 용도
FR2784678B1 (fr) 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
JP3422486B2 (ja) 1999-03-03 2003-06-30 サムジン ファーマシューティカル カンパニー リミテッド ピペラジン誘導体及びその製造方法
BR0009674A (pt) 1999-04-09 2002-01-15 Basf Ag Composto, droga, e, uso de composto
KR100799134B1 (ko) 1999-05-24 2008-01-29 미츠비시 웰파마 가부시키가이샤 페녹시프로필아민 화합물
JP2001158786A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 哺乳動物の外部寄生虫防除剤
JP2001158785A (ja) 1999-11-30 2001-06-12 Takeda Chem Ind Ltd 農薬組成物
DE60131138T2 (de) 2000-01-13 2008-08-14 Amgen Inc., Thousand Oaks Antibakterielle mittel
JP2001233861A (ja) 2000-02-22 2001-08-28 Ube Ind Ltd ピラゾールオキシム化合物、その製法及び用途
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0211030A (pt) 2001-06-18 2004-06-22 Applied Research Systems Derivado de pirrolidina oxadiazole, uso de um derivado de pirrolidina oxadiazole, composição farmacêutica contendo pelo menos um derivado de pirrolidina oxadiazole, método para preparação de um composto de pirrolidina oxadiazole
WO2003070236A2 (en) 2002-02-19 2003-08-28 Pharmacia Italia S.P.A. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
PL372246A1 (en) 2002-05-28 2005-07-11 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7015321B2 (en) * 2002-10-12 2006-03-21 The Scripps Research Institute Synthesis of non-symmetrical sulfamides using burgess-type reagents
CA2520172C (en) 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
AU2004267094A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
PT1801108E (pt) 2004-09-08 2012-12-03 Mitsubishi Tanabe Pharma Corp Composto de morfolina para o tratamento de inflamações
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US8034953B2 (en) * 2005-05-10 2011-10-11 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
KR20080026198A (ko) 2005-06-30 2008-03-24 안트로제네시스 코포레이션 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
DE102005060466A1 (de) 2005-12-17 2007-06-28 Bayer Cropscience Ag Carboxamide
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
JP4297449B2 (ja) 2006-05-12 2009-07-15 株式会社サクラクレパス 墨汁
US20080146624A1 (en) 2006-09-19 2008-06-19 Incyte Corporation Amidines as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
WO2008036643A2 (en) 2006-09-19 2008-03-27 Incyte Corporation Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008058178A1 (en) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
JP5399262B2 (ja) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009128521A1 (ja) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 システインプロテアーゼ阻害剤
RS53688B9 (sr) * 2008-07-08 2020-01-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indoleamin 2,3-dioksigenaze
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa

Also Published As

Publication number Publication date
PH12019500770A1 (en) 2020-09-21
ES2799582T3 (es) 2020-12-18
US9873688B2 (en) 2018-01-23
KR102370067B1 (ko) 2022-03-04
EA201690959A1 (ru) 2016-08-31
EP3066085A1 (en) 2016-09-14
AU2019200404A1 (en) 2019-02-07
KR102617531B1 (ko) 2023-12-27
IL245314A0 (en) 2016-06-30
CA2929552A1 (en) 2015-05-14
BR122020009912B1 (pt) 2022-11-01
CN105899498B (zh) 2019-01-25
EA033667B1 (ru) 2019-11-14
US20180244663A1 (en) 2018-08-30
CR20160252A (es) 2016-09-19
IL245314B (en) 2019-07-31
KR20210126157A (ko) 2021-10-19
EP3744715A1 (en) 2020-12-02
AR098343A1 (es) 2016-05-26
EA201991770A1 (ru) 2019-12-30
JP6633163B2 (ja) 2020-01-22
BR112016009786B1 (pt) 2021-01-05
JP2020019805A (ja) 2020-02-06
CN105899498A (zh) 2016-08-24
LT3066085T (lt) 2020-06-25
CN109810104A (zh) 2019-05-28
JP2020019806A (ja) 2020-02-06
US9321755B2 (en) 2016-04-26
SG10201803874PA (en) 2018-07-30
SI3066085T1 (sl) 2020-08-31
AU2014346647A1 (en) 2016-05-26
CA2929552C (en) 2022-05-17
JP2017500284A (ja) 2017-01-05
MX2019008378A (es) 2019-09-09
TW202100523A (zh) 2021-01-01
CR20190351A (es) 2019-10-07
AU2019200404B2 (en) 2021-03-04
US10280157B2 (en) 2019-05-07
MX366874B (es) 2019-07-29
PE20160863A1 (es) 2016-09-03
MY174254A (en) 2020-04-01
IL267773A (en) 2019-09-26
US20150133674A1 (en) 2015-05-14
PL3066085T3 (pl) 2020-11-02
WO2015070007A1 (en) 2015-05-14
CY1123164T1 (el) 2021-10-29
JP2019038811A (ja) 2019-03-14
PH12016500818B1 (en) 2016-06-20
TWI696618B (zh) 2020-06-21
CL2016001082A1 (es) 2016-12-09
TW201605817A (zh) 2016-02-16
NZ719822A (en) 2021-11-26
ME03792B (me) 2021-04-20
PH12016500818A1 (en) 2016-06-20
US20160221996A1 (en) 2016-08-04
EP3066085B1 (en) 2020-05-13
IL267773B (en) 2020-04-30
SG11201603433UA (en) 2016-05-30
RS60598B1 (sr) 2020-08-31
HUE049337T2 (hu) 2020-09-28
PT3066085T (pt) 2020-07-16
JP6883079B2 (ja) 2021-06-09
PE20220430A1 (es) 2022-03-29
TW202309014A (zh) 2023-03-01
TWI775079B (zh) 2022-08-21
DK3066085T3 (da) 2020-06-02
HRP20201089T1 (hr) 2020-10-30
KR20160094971A (ko) 2016-08-10
TWI651311B (zh) 2019-02-21
JP6461953B2 (ja) 2019-01-30
AU2014346647B2 (en) 2018-10-25
TW201920158A (zh) 2019-06-01
CN109810104B (zh) 2022-05-03
JP6913725B2 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
PH12019500770A1 (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
SA519401020B1 (ar) مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
NZ630196A (en) Cyclic amides as metap-2 inhibitors
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201792028A1 (ru) Альфа-цинамидные соединения и композиции как ингибиторы hdac8
MX2017006048A (es) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetrahidropiridi nas en calidad de inhibidores de bace1 para tratar enfermedad de alzheimer.
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201791030A1 (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
MX2021015656A (es) Formas amorfas y cristalinas de inhibidores de indolamina 2,3-dioxigenasa (ido).
DOP2016000120A (es) Nuevos inhibidores de dgat2
BR112015011974A2 (pt) derivados de azaquinazolina carboxamida
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
MX359556B (es) Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico.
EA201891761A1 (ru) Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение
AR099931A1 (es) Combinaciones de agentes terapéuticos contra cáncer
TH166656B (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
TH166656A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
EA201990556A1 (ru) Ингибиторы клеточных метаболических процессов
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-

Legal Events

Date Code Title Description
FG Grant or registration